Management tracks: Biogen’s McKenzie departing for CSL; plus Rubius, SanBio, Avita and more
Paul McKenzie is leaving Biogen Inc. (NASDAQ:BIIB) as EVP, pharmaceutical operations & technology to become COO of CSL Ltd. (ASX:CSL). A veteran of Johnson & Johnson (NYSE:JNJ), Bristol-Myers Squibb Co. (NYSE:BMY) and Merck & Co. Inc. (NYSE:MRK), McKenzie will be based at CSL Behring’s operational headquarters in King of Prussia, Pa., and will lead the company’s global end-to-end supply chain organization, including manufacturing and CSL Plasma. He assumes his new post June 3.
Rubius Therapeutics Inc. (NASDAQ:RUBY) said President Torben Straight Nissen will leave the cell therapy company at the end of July to focus on earlier stage platform companies at Flagship Pioneering, where he is a venture partner. Nissen will consult for Rubius into next year...